Literature DB >> 11266077

Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R.

C E Watson1, D I Draganov, S S Billecke, C L Bisgaier, B N La Du.   

Abstract

Serum paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated enzyme that hydrolyses aromatic esters, organophosphates and lactones and can protect low-density lipoprotein (LDL) against oxidation. These properties are influenced by a well-characterized polymorphism (Q192R) in human PON1. We now report the identification and characterization of a phenotypically similar, but genetically distinct polymorphism in rabbit PON1. This polymorphism in rabbits was detected by phenotyping sera obtained from 16 inbred rabbit strains and 20 outbred New Zealand White rabbits by paraoxonase/arylesterase activity. The genetic basis of the rabbit polymorphism was determined by DNA sequencing and found to reside in a region distinct from the human Q192R and M55L polymorphisms. Three variant nucleotides within exon 4 (corresponding to P82S, K93E and S1O1G) were found to segregate with the observed rabbit PON1 phenotypes (rPON1A and rPON1B). The rPON1A and rPON1B proteins were purified and compared to the two human isoforms (192Q and 192R). The human and rabbit PON1s displayed similar characteristics with respect to physical properties and substrate specificity. However, rPON1A and rPON1B hydrolysed a variety of substrates at different rates. The rPON1A was also at least three-fold more efficient at protecting LDL from oxidation than rPON1B. Our characterization of a rabbit PON1 polymorphism provides useful insights into important functional residues in PON1. In addition, due to the observed similarities between the rabbit and human polymorphisms, the rabbit may serve as a good model to examine the effect of human PON1 polymorphisms in disease development.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266077     DOI: 10.1097/00008571-200103000-00003

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  8 in total

1.  Association between paraoxonase-1 gene polymorphisms and risk of metabolic syndrome.

Authors:  Dor Mohammad Kordi-Tamandani; Mohammad Hashemi; Nooshin Sharifi; Mahmoud Ali Kaykhaei; Adam Torkamanzehi
Journal:  Mol Biol Rep       Date:  2011-05-15       Impact factor: 2.316

Review 2.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

Review 3.  Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis.

Authors:  Emanuele D'Amico; Pam Factor-Litvak; Regina M Santella; Hiroshi Mitsumoto
Journal:  Free Radic Biol Med       Date:  2013-06-21       Impact factor: 7.376

Review 4.  Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Authors:  Hong-Liang Li; De-Pei Liu; Chih-Chuan Liang
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

Review 5.  Pharmacogenetics of paraoxonases: a brief review.

Authors:  D I Draganov; B N La Du
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-25       Impact factor: 3.000

6.  Serum paraoxonase 1 activity in cats: analytical validation, reference intervals, and correlation with serum amyloid A and alpha-1-acid glycoprotein.

Authors:  Gabriele Rossi; Sara Meazzi; Alessia Giordano; Saverio Paltrinieri
Journal:  J Vet Diagn Invest       Date:  2020-08-17       Impact factor: 1.279

Review 7.  Acute Phase Proteins in Marine Mammals: State of Art, Perspectives and Challenges.

Authors:  Maria Elena Gelain; Federico Bonsembiante
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

Review 8.  Serum paraoxonase 1 (PON1) measurement: an update.

Authors:  Jose J Ceron; Fernando Tecles; Asta Tvarijonaviciute
Journal:  BMC Vet Res       Date:  2014-03-25       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.